key: cord-0809439-82k9da8g
authors: Sun, J.
title: Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination
date: 2022-01-27
journal: nan
DOI: 10.1101/2022.01.26.22269659
sha: 237e7f45105c1b791db50a5e21e5244b14b3dd62
doc_id: 809439
cord_uid: 82k9da8g

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S-specific total and neutralizing antibody (Ab) responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19 vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing Ab against D614G, Delta and Omicron in the BAL compared to COVID-19 convalescents, despite robust S-specific Ab responses in the blood. Further, mRNA vaccination induced significant circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using an animal immunization model, we demonstrate that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing Ab responses, especially against SARS-CoV-2 Omicron; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing Ab response, not only against the ancestral virus but also the Omicron variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during re-infection, but offer limited protection against breakthrough infection, especially by Omicron. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by Omicron and future variants.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint Abstract SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S-specific total and neutralizing antibody (Ab) responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19 vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing Ab against D614G, Delta and Omicron in the BAL compared to COVID-19 convalescents, despite robust S-specific Ab responses in the blood. Further, mRNA vaccination induced significant circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using an animal immunization model, we demonstrate that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing Ab responses, especially against SARS-CoV-2 Omicron; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing Ab response, not only against the ancestral virus but also the Omicron variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during re-infection, but offer limited protection against breakthrough infection, especially by Omicron. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by Omicron and future variants. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022.

The ongoing COVID-19 pandemic is a global public health crisis, and vaccination is considered the key to ending the pandemic (1, 2). It is well recognized that current SARS-CoV-2 vaccines, particularly mRNA-based vaccination, can induce robust humoral and cellular immunity and prevent severe disease caused by SARS-CoV-2 (3); however, protection against non-symptomatic to mild infection and transmission by mRNA vaccination is relatively moderate (4) , and the reasons for this are poorly defined. Notably, most of the previous studies were conducted using blood to determine circulating antibodies and B and T cell immunity following vaccination (5) , and characterization of respiratory mucosal immunity is lacking, which is essential for understanding vaccine-and natural infection-mediated protection against SARS-CoV-2. Additionally, the newest SARS-CoV-2 variant of concern (Omicron), has been shown to easily escape both vaccine and infection-elicited Ab neutralization in the blood (6) (7) (8) (9) (10) (11) (12) . However, it is currently unclear whether efficient mucosal neutralizing Ab responses can be induced by vaccination, and/or natural infection, and to what extent this could protect against SARS-CoV-2 infection. The current study was designed to address these critical questions, and our results demonstrated that robust mucosal immunity can be elicited in the lung by natural infection and mRNA vaccination plus adenovirus-mediated vaccination, but not by the mRNA vaccination alone, and that the induced mucosal immunity is essential for protection against infection by SARS-CoV-2, including the Omicron variant.

To determine the humoral and cellular immune responses following COVID-19 vaccination, we collected blood and BAL samples from a cohort of COVID-19-vaccinated individuals (Fig.1A) . Most of these individuals had received two doses of mRNA vaccination, with 3 individuals receiving the third booster and one having the J&J vaccine. The vaccine type, timing of collection, age, and sex information are included in Extended Table S1 . We compared the vaccine-induced respiratory and circulating Ab, as well as cellular immune responses, to those of hospitalized COVID-19 convalescents that we have previously recruited (13) . We first performed enzyme-linked immunoassay (ELISA) to determine and compared the SARS-CoV-2 S1 or receptor binding domain (RBD)-specific IgG, IgA and IgM levels in unvaccinated control (non-SARS-CoV-2 infected), vaccinated, and convalescent groups in the plasma. Similar to what was shown before (3, 14) , COVID-19 vaccination induced robust S1 or RBD-specific plasma IgG at levels comparable to severe cases of natural infection ( Fig. 1B and Fig. S1A ). The S1 or RBD-specific IgG levels in the BAL were also comparable between COVID-19-vaccinated and convalescent . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint groups ( Fig. 1C and Fig. S1B ). Of note, COVID-19 vaccination failed to induce significant levels of systemic S1 or RBD-specific IgA, while COVID-19 convalescents exhibited moderate but detectable S1-specific IgA responses in the blood ( Fig. 1D and Fig. S1C ). Importantly, prior severe SARS-CoV-2 infection provoked significant levels of S1 or RBD-specific IgA in the respiratory mucosa, which was not the case for COVID-19 vaccination ( Fig. 1E and Fig. S1D ). We also examined IgM in the blood and BAL, and observed that, while detectable levels of IgM were present in the circulation of both COVID-19-vaccination group and prior infection cases, only prior infection elicited significantly elevated IgM responses in the BAL (Fig. S1E-H) . Together, these results revealed that, in contrast to natural infection, COVID-19 vaccination does not provoke robust IgA or IgM responses in the respiratory tract.

The humoral protection against SARS-CoV-2 infection relies on the induction of robust neutralizing Ab (15) (16) (17) . We thus examined the plasma neutralizing Ab activity against SARS-CoV-2 D614G, Delta and Omicron spike-pseudotyped lentiviruses (18) (6) (7) (8) (9) (10) (11) (12) (19) (20) (21) .

We next compared neutralizing Ab responses in BALs of COVID-19-vaccinated and convalescent groups along with healthy controls. Despite the overall lower neutralizing antibody levels in BAL compared to that in the blood, the convalescent group showed ~3-fold higher neutralizing Ab activity than the vaccinated group, especially for the ancestral D614G (p < 0.05) and the Delta variant (p < 0.01) ( Fig. 2D -E). The titers for the Omicron variants were mostly below the level of detection (Fig. 2F ), reflecting the stronger escape of Omicron from neutralizing antibodies. Of note, one out of three who had received a booster vaccination exhibited above-the-threshold yet low level of neutralization activity against Omicron (Fig. 2F) , suggesting that booster vaccine may offer some, but limited, level of protection (Fig. 2F) . Overall, these results indicate that natural infection elicits stronger humoral immunity in mucosal surface compared to mRNA vaccination, and better vaccine strategies are needed to offer protections against VOC, especially the Omicron variant.

Although memory T and B cells do not confer sterilizing immunity, they are important in constraining viral dissemination and protecting against severe diseases once a virus breaches is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint neutralizing humoral immunity (15, (22) (23) (24) (25) . Both circulating and tissue-resident memory T and B cells are believed to provide disease protection against severe respiratory viral infection (22, (26) (27) (28) . We therefore examined systemic and tissue residing memory T and B cell responses following mRNA vaccination or natural infection. Compared to unvaccinated controls, vaccinated individuals had higher RBD-specific B cells in the blood (Fig. S3 A-D) . Notably, RBD-specific B cells were markedly lower in BAL compared to those of PBMCs ( Fig. 3A and Fig. S3E ). As reported before (22, (29) (30) (31) , vaccination induced notable S-specific TNF or IFN-g producing CD8 + or CD4 + T cells in the circulation, but failed to elicit strong S-specific cytokine-producing CD8 + or CD4 + T cell responses in the BAL (Fig. 3B , C and Fig. S4 ). In contrast, convalescent BAL exhibited much higher RBD-specific B cells compared to the paired blood samples (Fig. 3D ), suggesting that vaccination does not induce tissue-residing memory B cell responses as effectively as natural infection. Further, BAL from COVID-19 convalescents had higher cytokineproducing CD8 + and CD4 T + cells than those of blood (Fig. 3E , F and (13)). Within the total CD8 + or CD4 + T cell compartments, the levels of most memory T cell subsets in the blood and/or BAL were quite similar between unvaccinated or vaccinated individuals, except the blood TCM population (Fig. S4) . Thus, unlike SARS-CoV-2 natural infection, mRNA vaccination does not appear to induce significant SARS-CoV-2 specific B and T cell memory in the respiratory mucosa in contrast to that in the blood.

Given the suboptimal mucosal immunity induced by the current mRNA vaccination, we used an animal model to identify potential strategies that promote and/or amplify mucosal humoral and cellular immunity after mRNA vaccination. To this end, we immunized wildtype mice with PBS, two doses of mRNA-encoding codon-optimized S (mRNA-S), three doses of mRNA-S, two doses of mRNA-S plus an intranasal immunization of S protein trimer with adjuvant (STING ligand, cGAMP (32)), or two doses of mRNA-S plus an intranasal of adenovirus type 5 encoding S protein (Ad5-S) ( Fig. 4A ). We focused on intranasal immunization in mRNA-immunized mice, in keeping the contention that induction of mucosal immunity likely occurs in previously vaccinated individuals who will be willing to receive mucosal booster vaccines. mRNA plus Ad5-S vaccination induced greatly increased BAL RBD-specific B cells (Fig. 4B) . Furthermore, mRNA plus Ad5-S vaccination induced potent mucosal CD8 + and CD4 + T cell responses but not in the spleen (Fig. S5 ). mRNA immunization, with or without mucosal booster immunization, induced strong circulating S1 or RBD-specific IgG in the blood and the BAL (Fig. S6 A, B) . A third dose of mucosal immunization of S protein, with S trimer plus cGAMP or Ad5-S, resulted in significant increases of both S1 and RBD-specific IgA in the BAL (Fig. 4C) , with Ad5-S booster inducing the highest RBD-specific IgA in the respiratory mucosa. Ad5-S booster also generated significantly higher levels of plasma IgA than other groups (Fig. S6C) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint All immunized groups showed strong neutralization against D614G and the Delta variant in the plasma, although three-dose mRNA, or two-dose mRNA plus Ad5-S booster, vaccination induced higher levels of neutralizing Ab compared to two doses of mRNA immunization (Fig. S6 F, G) . As would be expected, the mouse plasma neutralization activities against Omicron were also dramatically reduced relative to D614G or Delta (Fig. S6 H) , indicating that Omicron is capable of escaping immunization-indued neutralizing Ab responses in the mouse blood similar to that in humans. However, we were still able to detect neutralizing Ab activities, at approximately similar levels, against the Omicron variant in all immunized groups (Fig. S6H) .

The neutralizing Ab activity in the BAL of mRNA immunized mice (two doses or three doses) were generally lower than those in the blood, but clearly detectable against D614G, with ~4-fold reduction in Delta, yet were around the limit of detection for the Omicron variant ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint Discussion mRNA vaccination elicited at least comparable neutralizing Ab levels as COVID-19 convalescents in the circulation, but generated considerably lower mucosal IgA and neutralizing Ab responses against SARS-CoV-2 D614G and Delta variants than those of convalescents, indicating that the overall magnitude of mucosal Ab responses is suboptimal following vaccination. Of note, the Omicron variant almost completely escaped the neutralization activity of BAL from either vaccinated or previously infected individuals. Additionally, we provide compelling real world evidence that mRNA vaccination does not induce notable tissue-residing S-specific memory B and T cells. Thus, despite the induction of robust circulating humoral and cellular immunity, current COVID-19 mRNA vaccines likely do not provoke sufficient levels of mucosal immunity in the human lower respiratory tract that would be needed for immediate clearance of the infectious Omicron strain to prevent the establishment of viral infection. Such a notion is consistent with the fact that Omicron continues to spread at a rapid pace in regions with high rates of vaccination and/or prior natural infection.

Our data do not dispute the notion that current vaccines are highly effective in preventing hospitalization and death. The prevention of severe disease after infection is conferred mainly by memory T and B cells (22, 33) . To this end, CD8 T cell epitopes within Omicron Spike protein remain conserved to those of ancestral strains (34, 35). Thus, even though Omicron is able to breach the defense of mucosal neutralizing Ab to cause infection, the recruitment of vaccineinduced circulating memory T cells during SARS-CoV-2 breakthrough infection enables protection that restrains further viral dissemination, preventing severe disease development following infection (Fig. S7 ). Nevertheless, these data suggest that mucosal humoral immunity is particularly vulnerable for immune escape by Omicron. It is thus quite likely that the current vaccine strategy, even with further boosters, will not achieve "herd immunity" or prevent the occurrence of new infections or re-infections with future VOCs, particularly those with immune-evasive properties like Omicron. Thus, our findings have significant public health implications.

Our data suggest that a mucosal SARS-CoV-2 booster vaccine may be necessary to achieve more robust immunity and protection from re-infection by future variants. To this end, we have provided a proof-of-principle experiment that systemic mRNA plus mucosal Ad5-S booster provoked strong cellular immunity in the respiratory tract, and compelling mucosal IgA and neutralizing activity against Omicron. Mucosal adenovirus delivery has potential concerns regarding safety and applicability on a large scale. However, if proven to be safe, such a platform would be of great translational and clinical relevance. Alternatively, a vaccine platform with viruslike nanoparticles (36), which can provide strong adjuvant activity and prolonged antigen presentation in vivo, may also be a promising approach to boost mucosal neutralizing immunity against Omicron or future VOCs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint Our study has several limitations. Due to the highly invasive nature of the BAL procedure, we were not able to recruit a large cohort of study participants. Furthermore, the study procedure made it challenging to time recruitment or perform a longitudinal analysis; rather it enabled a snapshot of vaccination or infection-induced mucosal immunity. Additionally, most of the participants were older and may not be representative of the entire vaccinated population, although this age group is considered as the primary targeting population for vaccination as they are at highest risk of infection associated with mortality and complications. These limitations need to be addressed by future studies. Nevertheless, we provide key evidence detailing mucosal humoral and cellular immunity following vaccination in the respiratory tract. Our study highlights the importance of focusing on vaccine-induced mucosal immunity (37) and argues for the necessity of a mucosal booster strategy in addition to the current approach of intramuscular COVID-19 vaccines.

We thank the study participants for their willingness to participate in the study. This work is partially funded by the US National Institutes of Health grants AI147394, AG047156 and AG069264 to J.S.; AI147394S1 to J.S. and R.V. This work in the Liu lab was supported by a fund provided by an anonymous private donor to The Ohio State University and NCI U54CA260582 to 

J.S. is a consultant for the Teneofour company, which does not directly involve with this project. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table 1 . and a previous publication (13) . Data are means ± SEM. Statistical differences were determined by one-way ANOVA and p values were indicated by ns, not significant (P > 0.05), * (p < 0.05), ** (p < 0.01), and **** (p < 0.0001). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Data are means ± SEM. Statistical differences were determined by one-way ANOVA and p values were indicated by * (p < 0.05), ** (p < 0.01), *** (p < 0.001) and **** (p < 0.0001).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. 

Fiberoptic bronchoscopy and BAL were performed using moderate conscious sedation using standard clinical procedural guidelines in an outpatient bronchoscopy suite. Conscious sedation was administered in accordance with hospital policies, and a suitably trained registered nurse provided monitoring throughout the procedure. The scope was wedged into an affected segment predetermined by review of CT scan. About 100 to 200 ml of saline were instilled in 20-ml aliquots until 60 ml of lavage fluid was obtained. The specimen was placed on ice and immediately hand carried to laboratory for analysis. The fluid collected was placed on ice and transferred immediately to the laboratory for processing.

Plasma was isolated from whole blood by centrifuging at 1,600 rpm, room temperature (RT), for 10 min. Plasma was collected and inactivated for 30 min at 56°C, then stored at −80°C for ELISA and neutralization assay. After plasma isolation, leftover blood was mixed with phosphate-buffered saline (PBS) and then gently put over on Ficoll-Paque (Cytiva, 17144002) in a 15 mL tube. Buffy coat generated by centrifuging at 400 g for 40 min at RT was collected. For single-cell purification from BAL, BAL was filtered with a 70-μm cell strainer (Falcon) and then centrifuged at 350 g for 6 min at 4°C. Supernatant was collected and aliquots were stored at −80°C for ELISA and neutralization assay. Supernatant of BAL was further concentrated for 20x using 3 kDa Amicon is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. 

General ELISA method has been previously described (13) . Briefly, recombinant SARS-CoV-2 proteins including RBD (Sino Biological, 40592-V08H), spike S1 D614G (S1, 40591-V08H3) (Sino Biological), were precoated to 96-well plates overnight at 4°C. The following day, plates were washed with wash buffer (0.05% Tween 20 in PBS) and then blocked with Assay dilution buffer (Biolegend, 421203) for 1 hour at RT. Plasma or 20x concentrated BAL from unvaccinated donors, vaccinated and convalescents were diluted in "Assay dilution buffer" starting at a 1:5 or 1:1 dilution, respectively, and then serially diluted by 5. Plasma from mice were diluted starting at 1:100 dilution, and then serially diluted by 5. BAL from mice was not concentrated or diluted.

Samples were added to the plate and incubated for 2 hours at RT. After washing three times with wash buffer, secondary antibodies diluted with "Assay dilution buffer" were added to the plate and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint STOP buffer. Plates were read at about 5 minutes on a microplate reader (Molecular Devices) at 450 nm with SoftMax Pro Software. The optical density (OD) value at 1:5 dilution for human plasma, 1:1 dilution for human BAL, 1:100 for mice plasma (1:500 for IgG), or original mice BAL were displayed, respectively; one dot represents each individual.

Virus neutralization assays were performed as previously reported (18) . Briefly, in a 96-well format, plasma or BAL were diluted starting at a 1:40 or 1:20 dilution, respectively, and then serially diluted by a factor of 4. The viruses were incubated with plasma or BAL for 1 hour at 37°C, 

General ELISA method has been previously described (13) . Fresh mice and human cells or frozen human PBMC or BAL cells recovered and rested overnight in 37°C, 5% CO2 incubator, were washed with FACS buffer (1% FBS and 0.5 M EDTA in PBS), then stained with antibodies as listed in Table. S2 for human and Table. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. ; https://doi.org/10.1101/2022.01.26.22269659 doi: medRxiv preprint at 4°C. CD44 + Tetramer + positive CD8 + T cells were identified as S539-546 epitope specific CD8 + T cells. Cell population data were acquired on a multi-spectral flow cytometer Cytek Aurora (Cytek Biosciences) or Attune NxT (Thermo Fisher Science) and analyzed using FlowJo Software (10.8.1, Tree Star). All human data from cytokines production assay were background-subtracted using paired DMSO treated control samples.

Statistical tests are indicated in the corresponding figure legends. One way ANOVA was used in multi group comparison. Paired t test was used in PBMC and BAL paired comparison. Others were analyzed using independent t test. All tests were performed with a nominal significance threshold of P < 0.05, which displayed by a single asterisk. P > 0.05 was displayed by ns, means not significant. Two asterisks indicate P < 0.01, Three asterisks indicate P < 0.001, four asterisks indicate P < 0.0001. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 27, 2022. NEW BAL S1 IgM #1  #2  #3  #4  #5  #8  #9  #10  #11  #12  #13  #14  #15  CON2  CON3  CON4  CON5  COV2  COV3  COV4  COV5  COV6  COV7  COV8  COV9  COV10  #16  #17  #18  CON7 NEW plasma S1 IgM NEW BAL RBD IgA NEW BAL S1 IgA NEW plasma RBD IgA NEW plasma S1 IgA NEW BAL S1 IgG NEW plasma S1 IgG #3  #4  #5  #6  #7  #10  #11  #12  #13  #14  #15  CON2  CON3  CON4  CON5  COV2  COV3  COV4  COV5  COV6  COV7  COV8  COV9  COV10  #16  #17   CON2  CON3  CON4  CON5  COV2  COV3  COV4  COV5  COV6  COV7  COV8  COV9  COV10  #16 Table S1 . Data in f and h are means ± SEM. Statistical differences were determined by oneway ANOVA and p values were indicated by ns, not significant (P > 0.05), * (p < 0.05), ** (p < 0.01), ***(p < 0.001) and **** (p < 0.0001). 

#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17#1 #2 #3 #4 #5 #8 #9 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9

#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9

#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9#1 #2 #3 #4 #5 #6 #7 #10 #11 #12 #13 #14 #15 CON2 CON3 CON4 CON5 COV2 COV3 COV4 COV5 COV6 COV7 COV8 COV9 COV10 #16 #17 #18 CON7 CON9

SARS-CoV-2 vaccines in development

The first 12 months of COVID-19: a timeline of immunological insights

Immunological mechanisms of vaccineinduced protection against COVID-19 in humans

COVID-19 vaccine breakthrough infections

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Evolution of enhanced innate immune evasion by SARS-CoV-2

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine&#x2013;elicited human sera

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Immune signatures underlying post-acute COVID-19 lung sequelae

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv

Adaptive immunity to SARS-CoV-2 and COVID-19

Tissue resident memory T cells and viral immunity

Tissue-resident CD4(+) T helper cells assist the development of protective respiratory B and CD8(+) T cell memory responses

Local memory CD4 T cell niches in respiratory viral infection

Co-Ordination of Mucosal B Cell and CD8 T Cell Memory by Tissue-Resident CD4 Helper T Cells

Immunity to respiratory viruses